Shopping Cart
Remove All
Your shopping cart is currently empty
STL001 is a potent and selective inhibitor of FOXM1. It triggers the translocation of nuclear FOXM1 to the cytoplasm, promoting autophagic degradation. STL001 enhances the sensitivity of human cancers to broad-spectrum cancer therapies.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | 10-14 weeks | 10-14 weeks | |
| 50 mg | Inquiry | 10-14 weeks | 10-14 weeks |
| Description | STL001 is a potent and selective inhibitor of FOXM1. It triggers the translocation of nuclear FOXM1 to the cytoplasm, promoting autophagic degradation. STL001 enhances the sensitivity of human cancers to broad-spectrum cancer therapies. |
| In vitro | STL001, in concentrations ranging from 1-10 μM over 24 hours, causes a dose-dependent reduction in cellular FOXM1 protein levels. At 5 μM for 24 hours, STL001 prompts the translocation of nuclear FOXM1 to the cytoplasm, enhancing its autophagic degradation. In U2OS-C3-luc cells, treatment with 5 μM for 24 hours resulted in decreased FOXM1 levels and elevated expression of the autophagy marker protein LC3. |
| Molecular Weight | 509.52 |
| Formula | C27H23N7O4 |
| Cas No. | 3047493-70-6 |
| Smiles | O=C(OC1=CC=CC(=C1)C2=NN(C=C2)C3=NC(=NC(=N3)N4CCOCC4)NC=5C=CC=CC5)C=6OC=CC6 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.